

Special Issue

Trust, Willingness, and Associated Factors towards COVID-19 Vaccine Uptake

Message from the Guest Editors

COVID-19 vaccination is one of the most successful and cost-effective health interventions to prevent and control SARS-CoV-2. It is important to understand trust, willingness, and other associated factors towards COVID-19 vaccines. This Special Issue will gather original reports, systematic reviews, and meta-analyses. Research areas may include, but are not limited to: (1) the levels and determinants of trust, hesitancy, willingness, and uptake of COVID-19 vaccination in the context where evidence is lacking, (2) the impacts of COVID-19 vaccination on SARS-CoV-2 infection, other health behaviors, and physical and mental health, (3) the facilitators and barriers to implementing COVID-19 vaccination programs, and (4) the evaluation of COVID-19 vaccination programs or interventions. We look forward to receiving your contributions.

Guest Editors

Dr. Zixin Wang

The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China

Dr. Paul Shing-Fong Chan

The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China

Deadline for manuscript submissions

closed (31 August 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/173618

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).